<?xml version="1.0" encoding="UTF-8"?>
<p>Currently, there are four marketed drugs for ameliorating the symptoms of Alzheimerâ€™s disease
 <xref rid="CIT0026" ref-type="bibr">
  <sup>26</sup>
 </xref> aiming at two therapeutic targets: the inhibitors of cholinesterases (acetylcholinesterase, AChE; and butyrylcholinesterase, BuChE) donepezil, rivastigmine and galantamine, which increase the levels of acetylcholine (
 <italic>cholinergic hypothesis</italic>), and the antagonist of 
 <italic>N</italic>-methyl-
 <sc>d</sc>-aspartic receptors (NMDA) memantine, for regulating glutamate levels in brain cells.
</p>
